RxDoctor Payments Data

Shannon McBain

Nurse Practitioner · Chico, CANPI 1427177054

Payments from drug & device makers

$2,429in general payments, 2019–2025

Across 88 payments — averaging $27.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$382
  • Abbott$301
  • Daiichi Sankyo Inc.$274
  • Novartis$233
  • Merck$192
  • Alnylam Pharmaceuticals Inc.$136
  • plus $911 from 15 others

What the payments were for

  • Food & beverage$2,429100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,429 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$171,074
Medicare patients
1,024
Services billed
4,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban540$617,884
EntrestoSacubitril/Valsartan250$278,017
XareltoRivaroxaban166$190,082
Repatha SureclickEvolocumab153$126,648
FarxigaDapagliflozin Propanediol41$44,791
JardianceEmpagliflozin31$30,951
Praluent PenAlirocumab35$23,881
BrilintaTicagrelor25$21,747
Metoprolol Succinate455$7,681
Atorvastatin Calcium577$6,075
Ezetimibe157$5,501
Diltiazem 24hr Er (Cd)Diltiazem Hcl119$4,990
Flecainide Acetate98$4,287
ClopidogrelClopidogrel Bisulfate296$4,158
Amiodarone Hcl133$3,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$382$617,884540 claims
NovartisEntresto$233$278,017250 claims
Johnson & JohnsonXarelto$79$190,082166 claims
AstraZenecaFarxiga, Brilinta$45$66,53866 claims
Boehringer IngelheimJardiance$15$30,95131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →